LLY

1,151.69

+0.06%↑

JNJ

237.15

+2.47%↑

ABBV

226.1

+1.53%↑

UNH

411.57

+1.32%↑

MRK

120.35

+1.25%↑

LLY

1,151.69

+0.06%↑

JNJ

237.15

+2.47%↑

ABBV

226.1

+1.53%↑

UNH

411.57

+1.32%↑

MRK

120.35

+1.25%↑

LLY

1,151.69

+0.06%↑

JNJ

237.15

+2.47%↑

ABBV

226.1

+1.53%↑

UNH

411.57

+1.32%↑

MRK

120.35

+1.25%↑

LLY

1,151.69

+0.06%↑

JNJ

237.15

+2.47%↑

ABBV

226.1

+1.53%↑

UNH

411.57

+1.32%↑

MRK

120.35

+1.25%↑

LLY

1,151.69

+0.06%↑

JNJ

237.15

+2.47%↑

ABBV

226.1

+1.53%↑

UNH

411.57

+1.32%↑

MRK

120.35

+1.25%↑

Inicio・Lista de Acciones・Kura Oncology Inc

Kura Oncology Inc

Abierto

SectorSanidad

8.69 1.76

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

8.49

Máximo

8.99

Métricas clave
By Trading Economics
Ingresos	7.7M -73M
Ventas	929K 18M
BPA	-0.828
Margen de beneficios	-401.495
Empleados	260
EBITDA	7.4M -78M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+228.39% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-42M 802M
Apertura anterior	6.93
Cierre anterior	8.69

Noticias sobre sentimiento de mercado

By Acuity

100%

320 / 344 Clasificación en Healthcare

Kura Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

8 jun 2026, 22:20 UTC

Adquisiciones, fusiones, absorciones

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8 jun 2026, 15:41 UTC

Principales Movimientos del Mercado

American Battery Shares Jump on Energy Department Victory

8 jun 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rebound After Monday's Selloff -- Market Talk

8 jun 2026, 23:37 UTC

Charlas de Mercado

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8 jun 2026, 23:25 UTC

Charlas de Mercado

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8 jun 2026, 23:25 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 jun 2026, 21:57 UTC

Adquisiciones, fusiones, absorciones

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8 jun 2026, 21:56 UTC

Adquisiciones, fusiones, absorciones

Salesforce Agrees to Buy m3ter

8 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

8 jun 2026, 19:22 UTC

Charlas de Mercado

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8 jun 2026, 19:01 UTC

Charlas de Mercado

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8 jun 2026, 18:52 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

8 jun 2026, 18:52 UTC

Charlas de Mercado

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8 jun 2026, 18:17 UTC

Charlas de Mercado

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8 jun 2026, 17:32 UTC

Charlas de Mercado

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8 jun 2026, 17:29 UTC

Charlas de Mercado

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8 jun 2026, 17:29 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 jun 2026, 16:55 UTC

Adquisiciones, fusiones, absorciones

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8 jun 2026, 16:54 UTC

Adquisiciones, fusiones, absorciones

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8 jun 2026, 16:40 UTC

Charlas de Mercado

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8 jun 2026, 16:31 UTC

Charlas de Mercado

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8 jun 2026, 16:27 UTC

Charlas de Mercado

Mexican Inflation Seen Easing in May -- Market Talk

8 jun 2026, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

8 jun 2026, 16:03 UTC

Adquisiciones, fusiones, absorciones

Orange Bought Stake From Lorca

8 jun 2026, 16:01 UTC

Adquisiciones, fusiones, absorciones

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8 jun 2026, 16:01 UTC

Adquisiciones, fusiones, absorciones

Orange Acquires 100% Ownership of MasOrange

8 jun 2026, 15:58 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

8 jun 2026, 15:58 UTC

Charlas de Mercado

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8 jun 2026, 15:55 UTC

Charlas de Mercado

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8 jun 2026, 15:41 UTC

Charlas de Mercado

Gold Falls Below 200-Day Moving Average -- Market Talk

Comparación entre iguales

Cambio de precio

Kura Oncology Inc previsión

Precio Objetivo

By TipRanks

228.39% repunte

Estimación a 12 Meses

Media 28.11 USD 228.39%

Máximo 40 USD

Mínimo 15 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Kura Oncology Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

320 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.